Takeda announces $30 million Indonesian plasma collaboration

• Takeda (NYSE:TAK) will invest up to $30 million in a multi-phased initiative to strengthen Indonesia’s plasma-derived medicinal product (PDMP) ecosystem.
• The Ministry of Health of the Republic of Indonesia granted Takeda a plasma fractionation license to facilitate local collection and processing.
• The company plans to launch a national plasma donation network pilot, with the first center expected to open in 2027.

Takeda (NYSE:TAK) and the Indonesian Government announced a landmark multi-year collaboration to enhance domestic health resilience and access to lifesaving therapies.

The initiative centers on the sustainable collection of high-quality plasma and the eventual manufacturing of plasma-derived medicinal products (PDMPs) within the country.

Takeda’s initial $30 million investment funds a two-year pilot program designed to establish plasma donation centers.

These centers will be integrated into Takeda’s existing BioLife network and adhere to international regulatory standards.

While the feasibility of a local manufacturing facility is under assessment, plasma collected during the pilot will be processed through Takeda’s global manufacturing network, prioritizing Indonesia's domestic supply needs.

The company anticipates this project will serve as a regional hub for plasma science and biopharmaceutical innovation.